肝病

订阅

MedSci主页 / 所有栏目 / 肝病

Sci Trans Med：乙肝新药进入临床阶段，有望彻底治愈乙肝

2017-11-07 佚名 medicalxpress

乙肝新药
关注

德州生物医学研究所西南国家灵长类动物研究中心(SNPRC)的研究人员们开始了慢性乙型肝炎病毒(HBV)新药的临床试验。测试结果显示，这种新颖的治疗方法和药物传递机制是安全有效的，研究结果发表在《国际科学转化医学》杂志上。

德州生物医学研究所西南国家灵长类动物研究中心(SNPRC)的研究人员们开始了慢性乙型肝炎病毒(HBV)新药的临床试验。测试结果显示，这种新颖的治疗方法和药物传递机制是安全有效的，研究结果发表在《国际科学转化医学》杂志上。

世界卫生组织认为乙肝是全球最主要的健康问题。据估计，有250万到4亿人长期感染了病毒。每年超过800000人死于肝硬化的并发症和肝癌。自1982年以来，疫苗有效预防乙肝感染的比例达到了95%，然而目前还没有治愈的慢性感染者达到数百万。

新型治疗药物使用一种称为RNA干扰的机制，用来减少慢性乙肝病毒的表面抗原，表面抗原(HBsAg)小分子参与病毒进入肝细胞。在慢性感染的过程中，他们可能会阻止免疫反应清除病毒。例如，高水平的表面会导致更大的长期风险，慢性感染乙肝，以及危及生命的并发症，如肝硬化、肝癌。在此，研究人员通过RNA的干扰而减少HBsAg，达到有益的影响。

在灵长类动物的试验中，研究人员已经证明针对乙肝病毒干预的实验药物安全有效，因此，大规模的人类试验才会开始。

研究人员解释说：“新疗法结合传统乙肝病毒治疗能使免疫系统杀死更多被感染的细胞，降低乙肝表面抗原，通过进一步的临床试验，我们将会确定这种新药是否可以治愈人类乙肝。”

原始出处：

Christine I. Wooddell,  Man-Fung Yuen, Henry Lik-Yuen Chan, et.al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Science Translational Medicine  27 Sep 2017

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2036330, encodeId=50d92036330ad, content=<a href='/topic/show?id=2a3f2343353' target=_blank style='color:#2F92EE;'>#乙肝新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23433, encryptionId=2a3f2343353, topicName=乙肝新药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Sat Jun 30 18:45:00 CST 2018, time=2018-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656906, encodeId=b5b2165690699, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sat Apr 14 08:45:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025279, encodeId=8bc720252e997, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Wed Aug 08 21:45:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608217, encodeId=b91c160821e31, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 09 11:45:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=259527, encodeId=e94025952e6d, content=是很好的学习材料.不错.以后会多学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Nov 07 21:33:15 CST 2017, time=2017-11-07, status=1, ipAttribution=)]
    2018-06-30 charl1234567

    #乙肝新药#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2036330, encodeId=50d92036330ad, content=<a href='/topic/show?id=2a3f2343353' target=_blank style='color:#2F92EE;'>#乙肝新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23433, encryptionId=2a3f2343353, topicName=乙肝新药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Sat Jun 30 18:45:00 CST 2018, time=2018-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656906, encodeId=b5b2165690699, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sat Apr 14 08:45:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025279, encodeId=8bc720252e997, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Wed Aug 08 21:45:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608217, encodeId=b91c160821e31, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 09 11:45:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=259527, encodeId=e94025952e6d, content=是很好的学习材料.不错.以后会多学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Nov 07 21:33:15 CST 2017, time=2017-11-07, status=1, ipAttribution=)]
    2018-04-14 bsmagic9140

    #TRA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2036330, encodeId=50d92036330ad, content=<a href='/topic/show?id=2a3f2343353' target=_blank style='color:#2F92EE;'>#乙肝新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23433, encryptionId=2a3f2343353, topicName=乙肝新药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Sat Jun 30 18:45:00 CST 2018, time=2018-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656906, encodeId=b5b2165690699, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sat Apr 14 08:45:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025279, encodeId=8bc720252e997, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Wed Aug 08 21:45:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608217, encodeId=b91c160821e31, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 09 11:45:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=259527, encodeId=e94025952e6d, content=是很好的学习材料.不错.以后会多学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Nov 07 21:33:15 CST 2017, time=2017-11-07, status=1, ipAttribution=)]
    2018-08-08 lixiao3326

    #临床阶段#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2036330, encodeId=50d92036330ad, content=<a href='/topic/show?id=2a3f2343353' target=_blank style='color:#2F92EE;'>#乙肝新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23433, encryptionId=2a3f2343353, topicName=乙肝新药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Sat Jun 30 18:45:00 CST 2018, time=2018-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656906, encodeId=b5b2165690699, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sat Apr 14 08:45:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025279, encodeId=8bc720252e997, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Wed Aug 08 21:45:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608217, encodeId=b91c160821e31, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 09 11:45:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=259527, encodeId=e94025952e6d, content=是很好的学习材料.不错.以后会多学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Nov 07 21:33:15 CST 2017, time=2017-11-07, status=1, ipAttribution=)]
    2017-11-09 ms3994565386320060

    #Med#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2036330, encodeId=50d92036330ad, content=<a href='/topic/show?id=2a3f2343353' target=_blank style='color:#2F92EE;'>#乙肝新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23433, encryptionId=2a3f2343353, topicName=乙肝新药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Sat Jun 30 18:45:00 CST 2018, time=2018-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656906, encodeId=b5b2165690699, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sat Apr 14 08:45:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025279, encodeId=8bc720252e997, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Wed Aug 08 21:45:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608217, encodeId=b91c160821e31, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 09 11:45:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=259527, encodeId=e94025952e6d, content=是很好的学习材料.不错.以后会多学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Nov 07 21:33:15 CST 2017, time=2017-11-07, status=1, ipAttribution=)]
    2017-11-07 李东泽

    是很好的学习材料.不错.以后会多学习.

    0

相关资讯

重视HBsAg突变隐患 应对乙肝防治新挑战

近日，“HBsAg突变全球多中心研究解读媒体会”在沪举行。台湾大学医学院高嘉宏教授、国家卫计委临床检验中心王露楠教授探讨了表面抗原（HBsAg）突变对临床及实验室检测带来的挑战和影响，HBsAg突变全球多中心研究负责人、罗氏诊断全球医学科学事务部Mikael Gencay博士则分享了该研究成果。

乙肝防治须重视乙肝表面抗原突变隐患

乙肝表面抗原（HBsAg）是乙肝病毒（HBV）感染后首先出现的血清学标志物，也是临床上应用最多的HBV感染血清标志物。由于HBV病毒的复制特点以及乙肝疫苗、抗病毒治疗的广泛应用，HBsAg突变在慢性HBV感染患者中非常常见。

乙肝治疗三个“不等于”

许多乙肝患者对长期治疗没有足够的心理准备，常常中断治疗。 为此，我总结了乙肝治疗中的3个“不等于”，有针对性地纠正一些误区。

AASLD2017: 又双叒叕刷存在感! “神药”阿司匹林可降低肝癌风险

如果要说全世界使用最广泛、知名度最高的药品，阿司匹林肯定是其中之一，且由于其用途广泛，更是赢得“世纪神药”的称谓。

Hepatology：干扰素-α对不同基因型乙肝病毒的作用研究！

干扰素-α（IFN-α）用于治疗慢性HBV感染，但是，只有20-40％的患者反应良好。临床观察表明，HBV基因型与IFN治疗的反应相关，然而，其在HBV感染肝细胞中对IFN的病毒反应性的作用尚不清楚。近期，一项发表在杂志Hepatology上的研究制造了HBV基因型A到基因型D的感染性病毒粒子，以感染三种基于细胞培养的HBV感染系统，包括原代人肝细胞（PHH），分化的HepaRG（dHepaRG）

Gastroenterology：新机制抗乙肝药物疗效优于恩替卡韦

研究发现，NVR3-778在模型中表现出高效持久的抗HBV病毒效果，NVR3-778联合干扰素的抗病毒效果优于恩替卡韦